Results 241 to 250 of about 153,892 (355)

Targeted siRNA Delivery Using Cetuximab‐Conjugated Starch for Epidermal Growth Factor Receptor‐Driven Head and Neck Squamous Cell Carcinoma

open access: yesSmall Science, Volume 5, Issue 7, July 2025.
A starch‐based carrier conjugated to cetuximab enables targeted siRNA delivery to epidermal growth factor receptor‐overexpressing tumors. The complexes exhibit dual passive and active tumor targeting, effective cellular uptake, and gene silencing, offering a versatile platform for RNA therapeutics in head and neck cancer.
Chen Benafsha   +10 more
wiley   +1 more source

From Bat to Worse: The Pivotal Role of Bats for Viral Zoonosis

open access: yesMicrobial Biotechnology, Volume 18, Issue 7, July 2025.
Thanks to a dampened inflammatory innate immune response, various Chiropteran (bat) species frequently carry ‐ without showing symptoms – diverse viruses that can cause severe diseases in humans. The reasons why bats are a pivotal virus reservoir for emerging viral diseases are discussed in this Lilliput contribution.
Harald Brüssow
wiley   +1 more source

Efficacy and Safety of Second‐Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study

open access: yesThoracic Cancer, Volume 16, Issue 13, July 2025.
Zhao et al. demonstrate the efficacy, survival and safety of second‐line immune checkpoint inhibitor rechallenge in advanced or metastatic esophageal squamous cell carcinoma patients. This provides a potential therapy option of second‐line treatment for esophageal squamous cell carcinoma patients after first‐line immunotherapy failure.
Wensi Zhao, Nan Zhao, Dedong Cao
wiley   +1 more source

Navigating Stomatologic Complications Secondary to Antineoplastic Agents-A Comprehensive Review. [PDF]

open access: yesCancers (Basel)
Popovici IA   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy